Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights
June 28th 2024Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.
Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study
June 28th 2024A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM
May 13th 2024In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.